Key facts
- It has raised $4.0M; the latest was Seed Round ($3.0M) in Aug 2025.
- Notable investors include Arieli Group, Hadasit, NGT HealthCare II, Yissum.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Hopec
- ·The full record, as it builds
Funding rounds
No funding rounds for Hopec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hopec
Operator of a pharmaceutical firm intended to develop an immunotherapy treatment for bladder cancer. The company focuses on the non-muscle-invasive bladder, it employs genetically modified uropathogenic coli for targeted immune responses against cells, enabling patients to destroy cancer cells.
- Sector
- Healthcare
- HQ
- Giv'at Shmuel, Israel
- Founded
- 2023
- Employees
- 6
- Website
- hopec-pharma.com/
- Ownership
- Privately Held (backing)
Hopec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hopec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hopec in its N-PORT filings yet. We sweep new filings monthly.